The China-based biotech was formed in 2018 by Ascendis Pharma and an investor syndicate led by Vivo Capital. The biotech is designed to develop and commercialize Ascendis’ endocrinology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback